Previous 10 | Next 10 |
Endonovo Therapeutics is developing a bioceutical device that provides an alternative to the prescription pain pills blamed for hundreds of thousands of deaths in recent years as part of a multinational opioid crisis Endonovo’s proprietary SofPulse® flagship device provides an...
As the U.S. attempts to address its opioid crisis, the need for safe and effective pain management solutions is growing Endonovo Therapeutics is making significant progress toward commercializing its SofPulse® device that delivers pulsed electromagnetic frequencies for pain managemen...
Endonovo Therapeutics (OTCQB: ENDV) , a commercial-stage developer of noninvasive Electroceutical® therapeutic devices, today announced its appointment of Dr. William Li as Strategic Advisor to the CEO. According to the update, Dr. Li and Endonovo CEO Alan Collier will work collaborative...
Los Angeles, CA, Sept. 30, 2019 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company") today announces it has appointed Dr. William Li as Strategic Advisor to the CEO. Dr. Li and Endonovo CEO Alan Collier will work collaboratively and strategically to ex...
Endonovo Therapeutics (OTCQB: ENDV) develops, manufactures and distributes innovative medical devices focused on the rapid healing of wounds and reduction of pain, edema and inflammation on and in the human body. The company’s SofPulse® Electroceutical® Therapy device employ...
Endonovo Therapeutics (OTCQB: ENDV) develops, manufactures and distributes innovative medical devices focused on the rapid healing of wounds and reduction of pain, edema and inflammation on and in the human body. An article discussing the company reads, “Dr. Peter Novak, who recently ...
Endonovo Therapeutics (OTCQB: ENDV) , a commercial-stage developer of noninvasive Electroceutical® therapeutic devices, today announced a partnership with Veterans Healthcare Supply Solutions to initiate SofPulse® sales to Veterans Health Administration and military hospitals. In ad...
LOS ANGELES, Sept. 09, 2019 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"), a commercial-stage developer of noninvasive Electroceutical® therapeutic devices, today announces a partnership with Veterans Healthcare Supply Solutions to initiate...
Endonovo Therapeutics (OTCQB: ENDV) , a commercial-stage developer of noninvasive Electroceutical(R) therapeutic devices, plans to have its innovative pain-management device available in all 50 states by 2020. An article discussing the company reads, “Technological advancements in the ...
Endonovo Therapeutics (OTCQB: ENDV) , a commercial-stage developer of noninvasive Electroceutical® therapeutic devices, this morning announced the appointment of orthopedic surgeon Dr. Geoffrey Abrams to its scientific advisory board. Dr. Abrams is an assistant professor of orthopedic su...
News, Short Squeeze, Breakout and More Instantly...
Endonovo Therapeutics Inc Company Name:
ENDV Stock Symbol:
OTCMKTS Market:
Endonovo Therapeutics Inc Website:
ADDvantage Technologies Group Inc. (AEYGQ) is expected to report for Q1 2024 ContraFect Corporation (CFRXQ) is expected to report for Q1 2024 American Clean Resources Group Inc (ACRG) is expected to report for Q1 2024 Atlantic Lithium Ltd Ord Fully Paid (ALLIF) is expected to report f...
Windtree Therapeutics Inc. (WINT) is expected to report for Q1 2024 CohBar Inc. (CWBR) is expected to report for Q1 2024 hopTo Inc (HPTO) is expected to report for Q1 2024 Bitech Technologies Corporation (BTTC) is expected to report for Q1 2024 Roadzen Inc. (RDZN) is expected to r...
Gelesis Holdings, Inc. (GLSHQ) is expected to report for Q1 2024 EVmo Inc (YAYO) is expected to report for Q1 2024 Chiba Bank Ltd. ADR (CHBAY) is expected to report for Q4 2024 Spark Networks SE (LOVLQ) is expected to report for Q1 2024 ToughBuilt Industries Inc. (TBLT) is expecte...